pharmaphorum

NOVEMBER 18, 2022

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. The post Provention finally gets FDA nod for type 1 diabetes drug teplizumab appeared first on.

Diabetes 52

Diabetes Immunity Immunization 52

Putting Patients First Blog

JULY 2, 2024

Clarification on QALY Metrics The NHC appreciates CMS’ commitment to excluding Quality-Adjusted Life Years (QALYs) from the negotiation process as outlined in the 2027 draft guidance. Valuing life differently based on disability status, age, or other special populations is inappropriate.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling HIPAA 52

European Pharmaceutical Review

JUNE 26, 2024

[the new facility will double] the combined square footage of all three of [Novo Nordisk]’s existing facilities in North Carolina” Overall, the expansion will support Novo Nordisk’s ability to produce injectable treatments for obesity and other chronic diseases such as diabetes. Completion is expected between 2027 and 2029.

Diabetes 104

Diabetes Pharmaceutical Companies Pharmaceutical Companies 104

European Pharmaceutical Review

NOVEMBER 20, 2023

Supporting European parenteral manufacture and supply Alongside expanding the company’s global parenteral product and device manufacturing network, the new facility will support the higher demand for Eli Lilly’s medicines, including its diabetes and obesity portfolio.

Diabetes 98

Diabetes 98

Pharmafile

JANUARY 25, 2023

Lilly’s expansion is set to include the addition of further parenteral filling, device assembly and packaging capacity in order to meet the growing demand for the company’s incretin-based diabetes treatments and medications. The facility is expected to become operational in 2027 and will create over 100 new jobs for manufacturing personnel.

Packaging 52

Packaging Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

APRIL 28, 2022

The US pharma has just reported top-line results from the first phase 3 trial of its dual GLP-1/GIP agonist tirzepatide as an obesity therapy that back up earlier results showing it can reduce the weight of people with diabetes. Over 72 weeks, patients taking a weekly injectable dose of tirzepatide lost up to 22.5% for the placebo group. .

Diabetes 52

Diabetes 52

Big Molecule Watch

DECEMBER 28, 2023

The patents-at-issue are directed to formulations and dosing regimens for aflibercept, an anti-VEGF treatment for retinal disorders including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The ’865 patent, which the court found to be valid and infringed, is expected to expire in June 2027.

Biosimilars 69

Biosimilars Diabetes 69

European Pharmaceutical Review

JANUARY 10, 2023

Treatments identified in the report are predicted to be potential blockbuster drugs by 2027 or have potential to serve unmet patient needs for millions of patients worldwide. Teplizumab (TZIELD /PRV-031) developed by Provention Bio Inc is the first immunotherapy to launch for type 1 diabetes mellitus (T1DM).

Drug Development 98

Drug Development Diabetes 98

pharmaphorum

OCTOBER 6, 2022

Lilly already has approval for the dual GLP-1/GIP agonist under the Mounjaro brand name as a diabetes therapy and is tipped to make rapid inroads in that market, with EvaluatePharma predicting sales could break the $1 billion barrier in 2024, and $3 billion two years later.

Diabetes 52

Diabetes 52

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. Diabetes Therapy. The Business Research Company.

Biosimilars 105

Biosimilars Diabetes Immunity Immunization 105

pharmaphorum

JANUARY 13, 2021

Symptoms are snoring and feeling sleepy during the daytime, but the underlying effects can be damaging and can lead to other health problems, including high blood pressure, heart attack, stroke and diabetes. The condition affects around 54 million people in the US alone.

Diabetes 59

Diabetes 59

Putting Patients First Blog

JANUARY 10, 2024

EHB-Benchmark Plans, Drug Formularies and Copay Maximizers: The NHC supports the proposed consolidation of State EHB-benchmark plan for PYs beginning on or after January 1, 2027, allowing States to select EHB-benchmark plans more effectively.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Communication Documentation Diabetes 40

PharmaShots

FEBRUARY 22, 2023

Approved Indications of Trulicity2 Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: As an adjunct to diet and exercise to improve glycaemic control in adults and paediatric patients (age: ≥10 years) with type 2 diabetes mellitus. million patients’ journeys with type 2 diabetes since 2014.

Diabetes 64

Diabetes Compounding Dosage Communication 64

Express Pharma

SEPTEMBER 12, 2023

HepaStem is projected to hit the US market in Q1 2027, while BioVie’s BIV201 is anticipated to be marketed in Q4 2028. As such, it is unsurprising that a stem cell therapy is being considered for the treatment of DC due to NASH. tumor formation, immune reactions, and therapy failure).

Diabetes 111

Diabetes Immunity Immunization 111

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

pharmaphorum

JANUARY 10, 2023

New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical “game changers,” according to Clarivate.

Labelling 52

Labelling Diabetes 52

Express Pharma

JANUARY 14, 2025

Due to their ability to effectively treat metabolic-related disorders, such as obesity and type 2 diabetes, the 11 approved GLP-1Rs generated sales of $37.2 With an expected launch in 2027, pemvidutide is forecast to generate sales of $1.21 Finally, Structure Therapeutics GSBR-1290 is in Phase II for obesity and type 2 diabetes.

Diabetes 105

Diabetes 105

Pharmaceutical Technology

NOVEMBER 30, 2022

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.

Insurance Coverage and Processing 105

Insurance Coverage and Processing Diabetes Labelling Communication 105

Pharmaceutical Technology

NOVEMBER 30, 2022

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.

Insurance Coverage and Processing 98

Insurance Coverage and Processing Diabetes Labelling Communication 98

European Pharmaceutical Review

NOVEMBER 18, 2024

Supporting production of diabetes medicine Development of the Lyon Gerland site enables internal production of a drug for patients with preclinical type 1 diabetes, previously produced outside the EU and not by Sanofi. These will be available for marketing from 2027, according to Sanofi.

Diabetes 64

Diabetes 64